Eli Lilly announced that the European Commission has granted a marketing authorisation for necitumumab (Portrazza), for use in combination with...
Eli Lilly and Company announced that the FDA has approved Portrazza (necitumumab injection for intravenous use, 800 mg/50 mL), in...
The UK National Institute for Health and Care Excellence has published final guidance and rejected Portrazza (necitumumab) from Eli Lilly...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...
The UK National Institute for Health and Care Excellence has published draft guidance that does not recommend approval for use...
The main purpose of this study is to evaluate if necitumumab added to standard chemotherapy of paclitaxel and carboplatin is...
The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.